Menu
← Oncology Approval Tracker
FDA DECISION ·
Sarclisa Escena + pomalidomide + dexamethasone
subcutaneous isatuximab-irfc with pomalidomide and dexamethasone · Sanofi
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with multiple myeloma after at least one prior treatment line that included lenalidomide and a proteasome inhibitor.
LAMPGEN ANALYSIS
Why it matters
The subcutaneous route changes administration in this combination. IRAKLIA compared the new route with IV isatuximab and used both response and drug exposure to assess noninferiority.
What research teams should watch
Plan staff training for on-body or manual delivery, administration reactions and documentation of complete dosing. Distinguish the subcutaneous formulation from IV preparation.
PRIMARY RECORDS